BIOMARIN PHARMACEUTICAL INC. — Net Income by Fiscal Year
18 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/3fdad5c1-66e1-4a57-bf1e-c83e18d04001/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $348.9M | 2025-01-01 – 2025-12-31 | evidence 0001628280-26-026290 |
| FY 2024 | $426.9M | 2024-01-01 – 2024-12-31 | evidence 0001628280-26-026290 |
| FY 2023 | $167.6M | 2023-01-01 – 2023-12-31 | evidence 0001628280-26-026290 |
| FY 2022 | $141.6M | 2022-01-01 – 2022-12-31 | evidence 0001628280-26-026290 |
| FY 2021 | $-64.1M | 2021-01-01 – 2021-12-31 | evidence 0001628280-26-026290 |
| FY 2020 | $854.0M | 2020-01-01 – 2020-12-31 | evidence 0001048477-23-000009 |
| FY 2019 | $-23.8M | 2019-01-01 – 2019-12-31 | evidence 0001048477-20-000009 |
| FY 2018 | $-77.2M | 2018-01-01 – 2018-12-31 | evidence 0001564590-19-005033 |
| FY 2017 | $-117.0M | 2017-01-01 – 2017-12-31 | evidence 0001564590-18-003114 |
| FY 2016 | $-630.2M | 2016-01-01 – 2016-12-31 | evidence 0001564590-17-002483 |
| FY 2015 | $-171.8M | 2015-01-01 – 2015-12-31 | evidence 0001564590-16-013653 |
| FY 2014 | $-134.0M | 2014-01-01 – 2014-12-31 | evidence 0001564590-15-001140 |
| FY 2013 | $-176.4M | 2013-01-01 – 2013-12-31 | evidence 0001193125-14-070025 |
| FY 2012 | $-114.3M | 2012-01-01 – 2012-12-31 | evidence 0001193125-13-077031 |
| FY 2011 | $-53.8M | 2011-01-01 – 2011-12-31 | evidence 0001193125-12-072924 |
| FY 2010 | $205.8M | 2010-01-01 – 2010-12-31 | evidence 0001193125-11-045527 |
| FY 2009 | $-488.0k | 2009-01-01 – 2009-12-31 | evidence 0001193125-11-045527 |
| FY 2008 | $30.8M | 2008-01-01 – 2008-12-31 | evidence 0001193125-11-045527 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
BIOMARIN PHARMACEUTICAL INC. — all facts · Revenue · Operating Income